Abigail Brooks, MA

Urinary cytokines GDF-15, IL-6, and EGF significantly strengthened the predictability of IgAN prognosis and may be viable biomarker candidates for disease progression.

The April 2024 month in review features HCPLive’s top coverage of resmetirom, other key hepatic pipeline updates, and recent research about hepatitis C virus.

In the first segment of this HCPLive special report, experts discuss the stigma surrounding alcohol use disorder and alcohol-associated liver disease.

Findings highlight an increase in hospitalization among pregnant patients with HCV, further describing age’s impact on mortality, cirrhosis, preterm births, and stillbirths.

This April 2024 month in review highlights World IBS Day, updates in the gastroenterology pipeline, ACP Internal Medicine meeting coverage, and recent IBD research.

Barratt explained findings from the phase 2b ORIGIN trial of atacicept and how it compares to current standard therapies in IgAN and other agents in the pipeline.

KDpredict uses age, sex, eGFR, and albuminuria to calculate 1-5 year risk of kidney failure and death in chronic kidney disease, outperforming the kidney failure risk equation.

Results showed a negative correlation between serum Gd-IgA1 and kidney function but found no association with several validated IgAN prognostic risk factors.

Tenofovir disoproxil fumarate was safe and effective for preventing mother-to-child transmission of HBV, but discontinuation was linked to postpartum hepatitis flares.

Solomon discusses the health care system’s role in mitigating climate change and how health care professionals can help protect and inform their patients.

Positive topline results showed treatment response consistent with NefIgArd findings, regardless of whether participants had previously been treated with Nefecon or placebo.

Solomon explains how the health care system contributes to climate change and the direct health impacts seen as a result, based on her session at ACP.

Branch provides an overview of the use of dual antiplatelet therapy and anticoagulants based on his session at the ACP Internal Medicine meeting.

Shah discusses the prevalence of psychiatric illness among hospitalized patients and highlights key considerations for their management from her session at ACP.

Nahas reviews key highlights from her session at ACP, emphasizing the importance of reviewing patient history and considering what other factors may be causing headaches.

Branch discusses key takeaways from his session at ACP and guideline recommendations for primary and secondary prevention of cardiovascular disease.

Contrary to previous research, findings point to similar decreases in weight and improvements in glucose homeostasis between time-restricted eating and usual eating pattern groups.

Markland discusses the use of anticholinergics, beta 3-agonists, and nonpharmacologic treatments for urge urinary incontinence, based on her session at ACP.

Wilt discusses the different screening methods recommended by ACP and explains how he talks about screening with his patients.

Berg discusses takeaways from his session at the 2024 ACP Internal Medicine meeting, including considerations for the diagnosis and management of acute coronary syndrome.

Cerceo discusses key topics from her session at the ACP Internal Medicine meeting about health care providers’ role in discussing climate-related health with their patients

In this Q&A, Kathuria explains the current state of smoking cessation programs and how health care providers can help patients combat their tobacco dependence.

Cerceo explains how the health care system contributes to climate change and the subsequent negative impact on patients, especially those in vulnerable or disadvantaged communities.

Lopez discusses the growing prevalence of obesity in the US and the need for improved, cross-specialty care based on patients’ metabolic health.

Wilt discusses ACP guidelines regarding what age to begin colorectal cancer screening and the benefits versus harms of screening at 45 compared to 50 years of age.

In recognition of World IBS Day, we spoke with Jeffrey Roberts about what led him to found the holiday in 2019 and took a closer look at the continued marginalization of the condition.

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.

The consensus calls for the recognition of kidney disease as a major non-communicable disease driver of premature mortality by the World Health Organization.

Incident use of anti-TNF therapy was linked to an increased risk of kidney function decline but not all-cause mortality in patients with newly diagnosed IBD.

Barratt discusses results from subgroup analyses of the phase 3 PROTECT trial based on baseline proteinuria and what they add to previous findings.